Ori Biotech’s mission to democratize access to cell and gene therapies

London and New Jersey-based cell and gene therapy (CGT) manufacturing technology firm Ori Biotech aims to accelerate CGT manufacturing processes. The company was highlighted on our recent roundup of prominent cell and gene therapy vendors in 2023.

In January 2022, the company secured more than $100 million in a Series B funding round, enabling the move from pre-commercialization to market launch. According to CEO Jason C. Foster, the company has grown from “three of us in the biotech equivalent of a garage” to 72 employees and raised $140 million in venture funding to date.

From investor to CEO of Ori Biotech

Jason Foster

Foster met the Ori team in 2018, working with them as an investor. He later joined full time as CEO after the company closed its first institutional round in 2019.

Ori Biotech has developed a proprietary platform that automates and standardizes CGT manufact…

Read more
  • 0

Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…
Read more
  • 0